Table 1.
Clinical characteristics of hepatoblastoma subjects (n = 87)
| Clinical characteristics at diagnosis | Study population n (%) |
|---|---|
| Sex | |
| Female | 29 (33.33%) |
| Male | 58 (66.67%) |
| Age (years) | |
| 0-3 | 66 (75.86%) |
| 3-7 | 15 (17.24%) |
| ≥8 | 6 (6.90%) |
| Maximal tumor diameter (cm) | |
| <10 | 34 (40.00%) |
| ≥10 | 51 (60.00%) |
| Serum AFP (ng/ml) | |
| ≤1000 | 2 (2.38%) |
| 1001-1000000 | 62 (73.81%) |
| >1000000 | 20 (23.81%) |
| PRETEXT stage | |
| I-III | 60 (74.07%) |
| IV | 21 (25.93%) |
| Metastasis | |
| Absent | 64 (73.56%) |
| Present | 23 (26.44%) |
| VPEFR | |
| Absent | 32 (42.11%) |
| Present | 44 (57.89%) |
| Histological category | |
| Pure fetal | 32 (36.78%) |
| HB with embryonal component | 37 (42.53%) |
| Others | 18 (20.69%) |
| Recurrence within 5 years | |
| Absent | 66 (77.65%) |
| Present | 19 (22.35%) |
| Death within 5 years | |
| Absent | 79 (92.94%) |
| Present | 6 (7.06%) |
AFP: alpha-fetoprotein; PRETEXT: pretreatment extent of disease; VPEFR: involvement of Vena cava or involvement of Portal vein or contiguous Extrahepatic intra-abdominal tumor extension or multiFocal liver tumor or tumor Rupture at diagnosis; HB: hepatoblastoma.